Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOD

Abstract

Objectives Treatment interruptions (TI) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur in resource-limited settings. We investigated the effects of TI associated with adverse events (AEs) and non-AE-related reasons, including their durations, on treatment failure after cART resumption in HIV-infected individuals in Asia. Methods Patients initiating cART between 2006-2013 were included. TI was defined as stopping cART for >1 day. Treatment failure was defined as confirmed virological, immunological or clinical failure. Time to treatment failure during cART was analysed using Cox regression, not including periods off treatment. Co-variables with p<0.10 in univariable analyses were included in multivariable analyses, where p<0.05 was considered statistically significant. Results Of 4549 patients from 13 countries in Asia, 3176 (69.8%) were male and the median age was 34 years. A total of 111 (2.4%) had TIs due to AEs and 135 (3.0%) had TIs for other reasons. Median interruption times were 22 days for AE and 148 days for non-AE TIs. In multivariable analyses, interruptions >30 days were associated with failure (31-180 days HR=2.66, 95%CI (1.70-4.16); 181-365 days HR=6.22, 95%CI (3.26-11.86); and >365 days HR=9.10, 95% CI (4.27-19.38), all p<0.001, compared to 0-14 days). Reasons for previous TI were not statistically significant (p=0.158). Conclusions Duration of interruptions of more than 30 days was the key factor associated with large increases in subsequent risk of treatment failure. If TI is unavoidable, its duration should be minimised to reduce the risk of failure after treatment resumption.

Stockouts of HIV commodities in public health facilities in Kinshasa: Barriers to end HIV

“…Stockouts of ARVs lead to delays in treatment initiation, unstructured treatment interruptions, and disengagement of patients with care [ 3 , 4 ]. These situations have negative consequences for individuals and populations, as they increase the risk of opportunistic infections, treatment failure, viral resistance and death [ 5 – 9 ]. The World Health Organization (WHO) considers any stockout of a routinely used ARV in an ART dispensary over the course of a year an early warning indicator for ART resistance [ 10 ].…”

Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon

“…However, up to 75% of adults on ART do not achieve viral suppression in SSA 3 , 4 . The reasons for this non-viral suppression are multifactorial and included non-adherence to ART 3 , 5 – 8 , treatment interruptions 5 , 9 , 10 , and sustained high viremia 8 , 10 , 11 . These factors lead to the emergence of drug resistant HIV and risks of onward transmission of drug resistance mutations (DRMs) 12 , 13 .…”

Are there differences in HIV retention in care between female and male patients in Indonesia? A multi-state analysis of a retrospective cohort study

“…We did not account for treatment interruptions, a relatively common occurrence among HIV patients [87] experienced by 97% of patients on ART in this population. Treatment interruption could correlate with treatment failure and retention in care [88,89]. In this cohort we had to censor 473 patients (15%) due to transfer because treatment data between facilities are not linked.…”